Artificial intelligence-assisted amphiregulin and epiregulin immunohistochemistry predicts panitumumab benefit in RAS wild-type metastatic colorectal cancer

Purpose High tumor mRNA levels of the EGFR ligands, amphiregulin (AREG) and epiregulin (EREG) are associated with anti-EGFR agent response in metastatic colorectal cancer (mCRC). However, ligand RNA assays have not been adopted into routine practice due to issues with analytical precision and practicality. We investigated whether AREG/EREG immunohistochemistry (IHC) could predict benefit from the anti-EGFR agent, panitumumab. Experimental Design...